The development potential of China's biomedical industry is huge, with an annual compound growth rate of 16%

[market analysis of chinapharma.com] according to the 2017 pharmaceutical market report of the industry, the global prescription drug market will grow steadily at a compound growth rate of 6.5% in the next five years, reaching US $1.06 trillion in 2022, among which biological products will grow steadily, accounting for 30% of the pharmaceutical market in 2022, reaching US $326 billion At present, China's biomedical industry is showing explosive growth, with an annual compound growth rate of 16% The industry is expected to continue to grow in the future, with huge development potential, mainly affected by policy, technological innovation and capital In recent years, China's biopharmaceutical industry has continued to adopt favorable policies On January 12, 2017, the national development and Reform Commission officially issued the 13th five year plan for the development of biological industry, which proposed that by 2020, the scale of biological industry would reach 8-10 trillion yuan On May 10, this year, the Ministry of science and technology formulated and issued the 13th five year plan for biological technology innovation, which clearly defined the target of the 13th five year plan for biological technology innovation and accelerated the development of Biomedical Innovation in China In addition, the launch of "healthy China 2030" and "several policies to accelerate the development of biomedical industry" and other relevant incentive policies have created a good environment for China's biomedical innovation and provided a favorable development platform for biomedical enterprises Technological innovation in recent years, with the gradual improvement of biotechnology industry platform and supporting industrial facilities, as well as the increasing support of relevant policies, the R & D strength of China's biomedical industry enterprises is also increasing, and a number of technologies are emerging on the world stage For example, in the field of stem cell research, China has also leaped to the forefront of the world, with individual directions in the "leading" position In addition, with the development of domestic biomedical industry, the demand for talents is also expanding According to industry data, at present, there are more than 1 million biomedical research and development forces in China, 30% of which have returned from overseas in recent years The accumulation of these talents will promote the further innovation and upgrading of China's biomedical industry Capital inflow into the market: according to the data, the scale of China's biomedical market in 2017 is about 145.8 billion yuan, which has become an important driving force for the growth of the global pharmaceutical market In this context, huge market potential will inevitably lead to the pursuit of capital In addition, with the acceleration of large-scale business restructuring in the pharmaceutical industry and the pull of business integration demand, it is bound to bring more impetus to the future M & A activities of biomedical enterprises According to the industry, through diversified capital operation modes such as investment, merger and acquisition, asset restructuring, etc., the concentration of pharmaceutical industry and Commerce will be further enhanced, the emerging fields such as innovative drug research and development, medical devices, internet medical care will be promoted, and the industrial structure will be optimized and upgraded In general, with the continuous increase of policy incentives for independent innovation in China, China's biomedical industry has achieved a basic synchronization with the global region in some high-end fields, such as PD-1, car-t, Ido inhibitors, IRNA and other fields In addition, with the development of big data and big health, China's biopharmaceutical industry has begun to move forward from the traditional development mode along with science and technology.